Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-11
2006-04-11
Ford, John M. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S223200, C514S228500, C544S061000, C544S113000, C544S180000
Reexamination Certificate
active
07026317
ABSTRACT:
The present invention relates to pyrazolotriazines according to formula (I)and stereoisomers, isomers and salts thereof wherein R1-R5are selected from certain alkyl, aryl and heteroaryl species as defined in the specification wherein all of the compounds are useful as CRF antagonists and are thus useful in the treatment of neurological disorders as well as a multitude of other CRF associated diseases or conditions.
REFERENCES:
patent: 3910907 (1975-10-01), O'Brien et al.
patent: 3920652 (1975-11-01), Springer et al.
patent: 3995039 (1976-11-01), Rooney et al.
patent: 4021556 (1977-05-01), Springer et al.
patent: 4567263 (1986-01-01), Eicken et al.
patent: 4621556 (1986-11-01), Soltysiak et al.
patent: 4892576 (1990-01-01), Kruger et al.
patent: 4997940 (1991-03-01), Vinogradoff et al.
patent: 5137887 (1992-08-01), Hashimoto et al.
patent: 5397774 (1995-03-01), Nugent et al.
patent: 5484760 (1996-01-01), Bussler et al.
patent: 6060478 (2000-05-01), Gilligan et al.
patent: 6124289 (2000-09-01), He et al.
patent: 6136809 (2000-10-01), Gilligna et al.
patent: 6191131 (2001-02-01), He et al.
patent: 6194410 (2001-02-01), Bos et al.
patent: 4243279 (1994-06-01), None
patent: 0 374 448 (1990-06-01), None
patent: 0 531 901 (1993-03-01), None
patent: 0 511 528 (1994-02-01), None
patent: 0 549 149 (1994-04-01), None
patent: 0 662 477 (1995-07-01), None
patent: 0 269 859 (1995-10-01), None
patent: 0 714 898 (1996-06-01), None
patent: 0 521 622 (1997-08-01), None
patent: 0 591 528 (1998-12-01), None
patent: WO 95/10506 (1995-04-01), None
patent: WO 95/35298 (1995-12-01), None
patent: WO 97/29109 (1997-08-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/38868 (1999-08-01), None
Deeb, A., et al., “Preparation of naphtha[2,1-e]pyrazolo[5,1-c][1,2,4]triazine, dipyrazolo[5,1-c:3',4'-e][1,2,4]triazines and pyrazolo-[1,5-c][1,2,4]triazine derivatives,”Collect. Czech. Chem. Commun, 1990, 55, 2790-2794.
Ege, G., et al. “Reactions with diazoazoles. Part IV. (1). [7+2]- and [11+2]-cyclocondensation reactions of diazoazoles with acyltriphenylphosphonium methylides to azolo[5,1cII1,2,4]triazines,”J. Heterocyclic Chemistry, Jun. 1981, 18(4), 675-677.
Gray, E.J., et al., “Triazines and related products. Part 21. Cyclisation of 3-amino-5-hydrazinopyrazole and 3-amino-5-hydrazino-1,2,4-triazole to azolo-[5,1-c][1,2,4]triazines,”J. Chemical Society, 1978, 885-888.
Ibrahim, et al.,Arch. Pharm. (Weinheim), 1987, 320, 487-491.
Joshi, et al.,J. Prakt. Chemie, 1979, 321 (2), 341-344.
Kandeel, E.M., et al., “Syntheses of new 2-aminopyrazolo[1,5-a]pyrimidines and 2-amino[1,5-c]-as-triazines,”Archiv der Pharmazie, (Weinheim), 1983, 316, 713-718.
Maquestiau, et al.,Bull. Scoc. Belg., 1992, 101(2), 131-136.
Ramiz, M.M.M., et al., “Studies on amino-azoles: synthesis of 3-methylaminopyrazole derivatives,”Arch. Pharm. (Weinheim), 1989, 322, 557-561.
Senga, K., et al., “Synthesis and enzymic activity of various substituted pyrazolo[1 5-a]-1,3,5-triazines as adenosine cyclic 3',5'-phosphate phosphodiesterase inhibitors,”J. Med. Chem., 1982, 25, 243-249.
Springer, et al.,J. Med. Chem.m 1976, 19(2), 291-296.
Strohmeyer, T.W., et al., “New synthesis of 2,4-dialkyl(or diaryl)pyrazolo[1,5-a]-1,3,5-triazines,”J. Heterocyclic Chem., Jan.-Feb. 1985, 22, 7-10.
J. Med. Chem.., 1981, 24, 610-613.
J. Het. Chem.., 1985, 22, 610.
Gilligan Paul J.
Wilde Richard G.
Bristol-Myers Squibb Pharma Company
Browder Monte R.
Ford John M.
Makujina Shah R.
Woodcock & Washburn LLP
LandOfFree
Pyrazolotriazines as CRF antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolotriazines as CRF antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolotriazines as CRF antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3608983